drugset / Trial / NCT01038752

Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer

NCT01038752

Phase 2 Terminated 14 enrolled Optimum Therapeutics, LLC
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the benefit of adding suramin at a non-cytotoxic dose to carboplatin and docetaxel regimen in the treatment of chemo-naïve patients with non-small cell lung cancer.

Timeline

Start
2010-08
Primary completion
2012-11
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject suramin Small molecule
Background Carboplatin Small molecule
Background Docetaxel Small molecule 56 mg/m2
Background Docetaxel Small molecule 75 mg/m2